Description:

Archigef (Gefitinib 250 mg Tablets) is a targeted anticancer therapy belonging to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). It is specifically designed for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors have activating EGFR mutations. Gefitinib selectively blocks the EGFR signalling pathway that plays a key role in the growth and survival of cancer cells.

Gefitinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the EGFR. By doing so, it blocks signal transduction pathways involved in the proliferation and survival of cancer cells with mutated or overexpressed EGFR.

Archigef is indicated for the treatment of:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations as determined by an approved diagnostic test.